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Abstract 
Pomegranate has been shown to prolong PSA doubling time in early prostate cancer, but no data 
from a placebo controlled trial has been published yet. The objective of this study was to pro-
spectively evaluate the impact of pomegranate juice in patients with prostate cancer.  
We conducted a phase IIb, double blinded, randomized placebo controlled trial in patients with 
histologically confirmed prostate cancer. Only patients with a PSA value ≥ 5ng/ml were included. 
The subjects consumed 500 ml of pomegranate juice or 500 ml of placebo beverage every day for 
a 4 week period. Thereafter, all patients received 250 ml of the pomegranate juice daily for another 
4 weeks. PSA values were taken at baseline, day 14, 28 and on day 56. The primary endpoint was 
the detection of a significant difference in PSA serum levels between the groups after one month of 
treatment. Pain scores and adherence to intervention were recorded using patient diaries. 
102 patients were enrolled. The majority of patients had castration resistant prostate cancer 
(68%). 98 received either pomegranate juice or placebo between October 2008 and May 2011. 
Adherence to protocol was good, with 94 patients (96%) completing the first period and 87 pa-
tients (89%) completing both periods. No grade 3 or higher toxicities occurred within the study. 
No differences were detected between the two groups with regard to PSA kinetics and pain 
scores. 
Consumption of pomegranate juice as an adjunct intervention in men with advanced prostate 
cancer does not result in significant PSA declines compared to placebo. 
Key words: Pomegranate juice, PSA, prostate cancer, nutraceutical, ellagig acids, polyphenols. 
Introduction 
Prostate cancer is the most commonly diagnosed 
cancer in men accounting for 29% of all male cancers 
and is the second leading cause of cancer-related 
death in the United States (American Cancer Society: 
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Cancer Facts and Figures 2011. Atlanta, Ga: American 
Cancer Society, 2011). Therefore, the identification of 
effective preventive strategies for prostate cancer is of 
particular clinical importance. Since free radicals seem 
to play a pivotal role in the development of prostate 
cancer reduction of intracellular free radicals by anti-
oxidants hold promise for disease prevention. How-
ever, in a large randomized trial (SELECT) the an-
ti-oxidant vitamin E has failed to show any benefit in 
the prevention of prostate cancer [1]. Polyphenols are 
anti-oxidants that have been shown to positively in-
fluence inflammation and cancer [2, 3]. A study uti-
lizing capsules containing polyphenols equivalent to 
12 cups of green tea found a significant reduction in 
serum levels of PSA, hepatocyte growth factor (HGF), 
and vascular endothelial growth factor (VEGF) in men 
with prostate cancer after a short treatment period [4]. 
Pomegranate juice (PJ) is a natural source of bioa-
vailable [5] ellagitannins and has been demonstrated 
to reduce redox activity [6]. As compared to red wine 
or green tea, pomegranate juice from commercial 
sources has an antioxidant capacity that is 3 times 
greater [7]. 
Pomegranate extracts contain ellagic acid, caffeic 
acid, luteolin and punicic acid, all of which have been 
associated with anti-cancer effects in preclinical mod-
els [6, 8]. 
Ellagic acids are considered the most active 
component of PJ, accounting for more than 50% of its 
antioxidant effects [7]. In a carcinogenic mouse model 
(TRAMP) oral pomegranate extract supplementation 
results in significant tumor control by inhibiton of 
IGF-I/Akt/mTOR pathways in the prostate tissues 
and tumors [9]. Pantuck and colleagues performed a 
single center, open-label study, examining the effect 
of PJ in men with rising PSA levels after surgery or 
radiation [10]. The investigators found an impressive 
increase in the PSA doubling time (PSADT) from 15 to 
54 months under the treatment (p< 0.001). Another 
study [11] tested pomegranate juice extract capsules 
in men with rising PSA levels after local therapy for 
prostate cancer (NCT01220817). Again, a statistically 
significant increase of the PSADT for one or three 
capsules daily (overall 11.9 to 18.5 months, p<0.001) 
was observed. In both studies a relevant proportion of 
men even showed a decrease of PSA serum levels due 
to consumption of PJ (15% and 13%). An on-going 
phase III study (NCT00413530) is examining whether 
the pomegranate liquid extract prolongs PSADT in 
patients who have rising serum PSA levels after pri-
mary therapy for localized prostate cancer. That ran-
domized, double-blind, placebo-controlled study with 
an estimated enrollment of 200 patients was sched-
uled to close on December 2012. All of the above 
studies have focused on the role of PJ in patients with 
early biochemical failure after initial treatment. No 
data about a therapeutic impact of PJ in patients with 
more advanced or metastatic prostate cancer has been 
published yet. A standard procedure for patients 
having failed hormone ablation therapy would be the 
initiation of chemotherapy [12, 13]. In the absence of 
symptoms the time point of starting chemotherapy is 
debatable hence patients and physicians often prefer 
to delay the start of this rather aggressive treatment. 
In our trial we report the influence of PJ compared to 
placebo in a cohort of asymptomatic or oligosymp-
tomatic patients, the majority (68%) of which had 
castration resistant prostate cancer.  
Patients and Methods 
Eligibility criteria 
Patients with histologically proven prostate 
cancer and a pathologic serum PSA (entry level at 
least 5 ng/ml) were eligible for the study. While pa-
tients were on study they had to continue their base-
line treatment (e.g. androgen deprivation, zoledronic 
acid). The initiation of any new potential active 
treatment was not allowed. Exclusion criteria were 
any planned therapeutic intervention such as surgery, 
irradiation or any alteration of the ongoing therapy, 
e.g. withdrawal of medication or introduction of new 
drugs during the study period.  
Design and assessments 
The study was conducted at two Swiss centers 
(University Hospital Zurich and KS Graubünden) and 
designed as a phase IIb, double-blind, place-
bo-controlled randomized trial. Consenting patients 
with a documented PSA above 5 ng/ml and histo-
logically confirmed prostate cancer were randomized 
into two groups. Group A received 500 ml placebo 
juice per day and Group B 500 ml of PJ (equivalent to 
1147 mg polyphenol gallic acid) per day. PSA serum 
levels were measured the day before treatment start-
ed, and on days 14 and 28. Patients were given a diary 
to document their daily juice intake, any adverse 
events and their pain score with time and date. The 
intensity of pain was self-documented by the previ-
ously instructed patients by choosing a value from a 
non-linear scale (range 0-10). At day 29 patients en-
tered the open label phase of the trial. In this second 
period of the study, 250 ml of PJ (equivalent to 573 mg 
polyphenol gallic acid) was consumed by all patients 
(bottles labelled C) and the diaries were continued as 
before. A final PSA serum value was taken on day 56. 
While on study, especially in the first period, patients 
were not informed about their current PSA values. No 
other diagnostics, e.g. CT-scans or laboratory values 
were part of this study. The relatively short observa-
tional period of 8 weeks was chosen because the pro-
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jected patient collective often converts from watchful 
waiting to intervention due to disease progression.  
Treatment 
Block randomization (block size 4) was used to 
assign patients to the treatment groups 500 ml PJ or 
placebo daily. The patients were instructed to drink 
one bottle of 500 ml per day; the timing was left to the 
patient´s discretion. Consumption was self- moni-
tored by daily recording using diaries. In addition, 
episodes of pain and usage of analgesics were also to 
be recorded by the patients in their diary.  
The producer of the beverage (Biotta AG, 
Egnach, Switzerland) provided the pomegranate juice 
and the placebo. Both beverages had a very similar 
taste and color (Supplementary figure 1). The juices 
contained the same basic ingredients, pear purée, 
white tea, agave concentrate and aronia berry juice. In 
the placebo drink the 27.5% pomegranate extract was 
replaced with an artificial pomegranate flavoring 
substance. The pomegranate juice contained 2294 
mg/l polyphenol gallic acid. The daily intake in the 
intervention arm was 1147 mg/day polyphenol gallic 
acid during the first study period and 573 mg/day 
polyphenol gallic acid in the second period of the 
study. 
The company supplied PJ and placebo and gave 
limited financial support. The company had neither 
influence on the acquisition of the data nor on the 
statistical analysis. The investigational sites received 
identical bottles labelled with A, B and C. Bottles A 
and B were distributed to the patients according to the 
predefined randomization scheme in the first study 
period. Bottles labelled C were given to all patients in 
the second study period. Information which letter 
corresponded to pomegranate or placebo was kept 
secret at the company and was not revealed to the 
investigators and the study personnel before the end 
of the study. Unblinding was not done before all sta-
tistical analysis had been performed. 
PSA testing 
The majority of patients´ PSA serum levels (75%) 
was determined by a third generation assay (chemi-
luminescence-enzyme-immunoassay, third genera-
tion Immulite 2500, Siemens healthcare diagnostics, 
Eschborn, Germany) at the Institute of Clinical 
Chemistry, University Hospital Zurich, Switzerland. 
All patient sera from Chur (n=23) were tested with an 
assay according to the ECLIA principle (Electro-
ChemiLuminescenceImmunoAssay, cobas e411, 
Roche diagnostics, Mannheim, Germany) at the cen-
tral laboratory of Kantonsspital Graubünden, Chur, 
Switzerland. 
For the report of this study PSA progression was 
defined as PSA increase ≥25% [14] and PSA response 
was defined as a decline of PSA ≥50% from baseline 
according to the recommendations from the PSA 
working group [15]. Patients with a PSA decline >30% 
are also reported here, as a PSA decrease of >30% 
under active treatment within the SWOG 99-16 study 
has been associated with a 50% reduction in the risk of 
death from prostate cancer [16]. Following the rec-
ommendation of the Prostate Cancer Clinical Trials 
Working Group PSA responses of the individual pa-
tients are shown in waterfall plots [17]. 
Statistical analyses 
Fisher’s exact test was used to compare categor-
ical data between groups and Mann-Whitney test for 
continuous data. Applying Wilcoxon signed rank test 
PSA levels between follow-up and baseline in the 
same group were evaluated. The aim was to show a 
difference of change scores before and after interven-
tion as well as before and in between the treatment. 
With an estimation of 47 patients in each arm the 
study was calculated to have a power of 85% to detect 
a difference of 5ng/ml (the difference of a group A 
mean of 0 ng/ml and group B of – 5 ng/ml) under the 
assumption of a standard deviation of 8 ng/ml, if a 
two group t-test with a double sided significance of 
0.05 was used. Statistical comparisons of patient 
characteristics were performed with Graphpad Prism 
5 software (Graphpad Inc. La Jolla, USA). 
Ethics and registration 
This study was approved by the local Ethics 
Committee (# EK-1545) and registered at “Deutsches 
Krebsstudienregister der Deutschen Krebsgesell-
schaft” (www.studien.de) under the study ID No.555.  
Results 
Patient characteristics 
Between October 2008 and May 2011 a total of 
102 patients with prostate cancer gave written consent 
and were enrolled. Of those, 5 patients were found 
ineligible as they did not fulfill the inclusion criteria. 
The trials profile is shown in Figure 1. Baseline char-
acteristics of the 97 patients in the full analysis popu-
lation are summarized in Table 1. With respect to 
ongoing treatment, 38% (18/47) of patients in the 
placebo group and 46% (22/48) in the verum group 
were under anti-hormonal treatment (LHRH ana-
logues). Some patients received bicalutamid in com-
bination or as a sole antihormonal treatment (22% in 
group A and 27% in group B). Low dose steroids 
(prednisone 5-10mg) were recorded in 4% of all pa-
tients (2% vs. 6%). 27% (25/94) study patients re-
ceived no treatment but were under a watch and wait 
strategy. No patient received chemotherapy or un-
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derwent surgery or irradiation while on study. Statis-
tically significant differences in tumor size (T3; 31% in 
the control vs. 51% in the intervention group, p=.036) 
and distant tumor spread (M1; 18% in controls vs. 
44%, p=.032) at the time of initial diagnosis were ob-
served (Table 1). Apart from these two variables the 
study was well balanced.  
 
Figure 1. Trial profile. 
Table 1. Patients’ characteristics. 
Characteristics Placebo (n= 46)  Pomegranate (n= 48) P 
Age (y) 72±8.4 73±8.6 NS 
Age > 64 yrs 40 36 NS 
Age > 69 yrs 29 29 NS 
ECOG PS 0 74% 75% NS 
ECOG PS 1 20% 21% NS 
ECOG PS 2 7% 4% NS 
Gleason Score <8 57% (20/35) 46% (16/35) NS 
Gleason Score ≥8 43% (15/35) 54% (19/35) NS 
TNM at diagnosis    
T0 4% (1/29) 0% (0/35) NS 
T1 17% (5/29) 17% (6/35) NS 
T2 41% (12/29) 17% (6/35) NS 
T3 31% (9/29) 51% (18/35) .036 
T4 7% (2/29) 15% (5/35) NS 
N0 78% (22/28) 55% (17/31) NS 
N1 22% (6/28) 45% (14/31)  NS 
M1 18% (5/28) 44% (15/34) .032 
At study entry    
PSA (Median, Mean, SD) 19, 90±222 ng/ml 21, 60±82 ng/ml NS 
CRPC 67% (31/46) 63% (30/48) NS 
Treatment (previous and ongoing)*    
RP 17% (8/46) 15% (7/48) NS 
RT 24% (11/46) 17% (8/48) NS 
RP+RT 22% (10/46) 11% (5/48) NS 
Watchful waiting 26% (13/46) 29% (14/48) NS 
ADT (continued) 39% (18/46) 46% (22/48)  NS 
Docetaxel 15% (7/46) 10% (5/48) NS 
NS= not significant, CRPC= castration resistant prostate cancer.  
Data presented as mean ± standard deviation or n (%).  
n=0 for ECOG> and n=0 for Gleason Score <5 and n=0 for N3 status.  
RP radical prostatectomy; RT, radiotherapy; ADT, Androgen deprivation therapy.  
TNM documented at diagnosis.  
* percentages in the treatment section do not add up to 100%, as patients may have had multiple interventions. 
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Safety 
Pomegranate juice was generally well tolerated 
with no grade 3 or 4 toxicities. Bowel disturbances 
were the most frequent adverse event reported. Ob-
stipation was observed in both groups: 2/46 (4%) in 
the placebo group and 1/48 (2%) in group B. One pa-
tient on placebo withdrew his consent due to a CTC 
grade 2 obstipation. One patient in the PJ group re-
ported a CTC grade 1 diarrhea (1/48; 2%) but no di-
arrhea was reported from patients in the placebo arm. 
The adherence to the protocol was good, with 94 
patients (96%) completing the first period (days 1-28) 
and 87 patients (89%) completing both periods (days 
1-56). Three patients dropped out within the first 28 
days due to unrelated medical problems. The other 
seven patients were unable or unwilling to complete 
the second period. Thus, 94 patients were eligible for 
analysis of the randomized part of the study and 87 
patients (42 patients in the placebo group A or 45 in 
the PJ group B) completed the full trial protocol. 45 
patients of group B could be analyzed for both dos-
ages of the pomegranate juice.  
Efficacy 
The number of patients experiencing a PSA de-
crease during the placebo-controlled period of the 
study was not statistically significant between the two 
arms (table 2). PSA progression within the first four 
weeks was observed in 41% in the control group 
compared to 38% in the pomegranate group (p=0.83). 
There were no responses with PSA decline >50% in 
either group, but 1 patient in the placebo group and 3 
patients in the pomegranate group showed a decline 
≥30% (Table 2A). In the second period of the study, 
when all patients consumed 250 ml of PJ, PSA pro-
gression was observed at a rate of 24% in the former 
placebo group and 29% in those patients that had 
been given 500 ml PJ in the first period (group B), 
(p=0.63, Table 2A). Despite the nominal reduction of 
patients with PSA progression in the placebo group 
the difference between the non-interventional period 
(day 1-28) and the pomegranate consumption period 
(day 29-57) was not significant (p=0.11). 
To address the question whether heterogeneity 
within the patient populations may have had an in-
fluence subgroup analysis were performed (Table 2B 
and 2C). Patients were pooled according to their sta-
tus of disease at study entry e.g. castration resistant 
prostate cancer (CCRPC) (n=61) and non CCRPC 
(n=33). These analyses as shown in table 2B and 2C 
revealed no difference for PJ or placebo in patients 
with regard to their hormonal response. The corre-
sponding waterfall plots depicting individual PSA 
changes are shown in figure 2. 
A combined PSA level analysis of both study 
periods showed PSA stabilization in 74% of patients 
starting with placebo versus 71% of those patients that 
had been under PJ continuously. The patients re-
ported pain values in the range from 0-5 at study en-
try without significant group differences (mean pain 
score A=0.97 and B=0.98; p=0.49). After the random-
ized phase of the study, at day 28, no relevant pain 
decrease was found in either group. A non-significant 
trend toward lower pain scores was seen in group B 
(mean day 1: 0.98 ±1.25 versus mean day 28: 0.62 
±1.13; p=0.092). 
 
   
Figure 2: Waterfall plots of percentage PSA changes from patients within the first period (day 1-28) 2A and the total period (day 1-56) 2B. 
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Table 2: Response evaluation. 
treatment PSA Progression PSA Stabilisation response* 
2A       
intention to treat     
Day 1-28** 
A Placebo (n=46) 19 (41%) 26 (57%) 0 (0%), 1 (2%) 
B PJ high (n=48) 18 (38%) 27 (56%) 0 (0%), 3 (6%) 
Day 28-56 
A PJ low (n=42) 10(24%) 31 (74%) 0 (0%), 1 (2%) 
B PJ low (n=45) 13 (29%) 31 (69%) 0 (0%), 1 (2%) 
Day 1-56 
A Placebo+PJ low (n=42) 18 (43%) 21 (53%) 1 (2%), 1 (2%) 
B PJ high+low (n=45) 18 (40%) 24 (53%) 0 (0%), 3 (7%) 
 
2B 
patients with CRPC       
Day 1-28** 
A Placebo (n=31) 16 (52%) 14 (45%) 0 (0%), 1 (3%) 
B PJ high (n=30) 12 (40%) 16 (53%) 0 (0%), 2 (7%) 
Day 28-56 
A PJ low (n=27) 10(37%) 16 (59%) 0 (0%), 1 (4%) 
B PJ low (n=28) 12 (43%) 15 (54%) 0 (0%), 1 (3%) 
Day 1-56 
A Placebo+PJ low (n=27) 15 (56%) 11 (40%) 1 (4%), 0 (0%) 
B PJ high+low (n=28) 16 (57%) 11 (39%) 0 (0%), 1 (4%) 
 
2C 
patients without CRPC       
Day 1-28** 
A Placebo (n=15) 3(20%) 12 (80%) 0 (0%), 0 (0%) 
B PJ high (n=18) 4 (22%) 12 (67%)  0 (0%), 2 (11%) 
Day 28-56 
A PJ low (n=15) 3(20%) 11 (73%) 1 (7%), 0 (0%) 
B PJ low (n=17) 1 (6%) 16 (94%) 0 (0%), 0 (0%) 
Day 1-56 
A Placebo+PJ low (n=15) 3(20%) 11 (73%) 0 (0%), 1 (7%) 
B PJ high+low (n=17) 3 (17%) 12 (71%)  0 (0%), 2 (12%) 
*Objective response (PSA) defined as PSA decline >50% in bold, responses ≥ 30% in italics  
**Day 1-28 represents the placebo-controlled phase of the study 
Progressive disease was defined as a PSA increase of ≥ 25% 
Stable disease were all PSA values between OR and PD. 
PJ high refers to a daily intake of 1147 mg/day polyphenol gallic acid (first period)  
PJ low 573 mg/day polyphenol gallic acid consumed by all subjects from day 28 on (second period) 
p-values not displayed as there were no significant differences 
 
Discussion 
The objective of this study was to assess the im-
pact of pomegranate juice on PSA levels in patients 
with advanced prostate cancer. There were no signif-
icant differences with regard to PSA levels or pain 
intensity between the observed groups in this trial. 
The study design included two treatment periods: 
Initially, patients were randomized to placebo (group 
A) or pomegranate juice consumption (group B). The 
results from the double-blinded, randomized con-
trolled part of the study show no differences with 
regard to PSA level rise or decline, pain, frequency of 
dropout or adverse effects. The fact that 35% of men in 
the control group and 25% in the intervention group 
had a decline in their PSA value during the first phase 
of the study is remarkable. A possible explanation for 
this phenomenon could be a natural fluctuation of 
serum PSA levels in a four-week period in men with 
advanced prostate cancer that has not been recorded 
to this extend until now. The latter is particularly 
important when interpreting results from earlier and 
on-going studies that report on declining PSA levels 
due to specific interventions. An alternative explana-
tion for the high percentage of men experiencing a 
PSA decline in both groups could be an unanticipated 
PSA test-to-test variability. With regard to this, an 
intermediate PSA level measurement had been pre-
defined in the study at day 14. The majority of PSA 
levels obtained at day 14 and at day 28 were in ac-
cordance with the individual PSA course, e.g. if day 
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14 and 28 values were not pointing in the same direc-
tion, no more than a 10% difference of the day 14 
value versus one of the other values was observed. 
Furthermore, test variability was controlled by pro-
cessing all individual blood samples at the enrolling 
institution. Thus, there was no variability regarding 
the test used or the laboratory where the set of four 
patient’s samples was analyzed. We conclude that test 
instability did not influence the final results. Another 
factor in this study that might have had an impact on 
patients with declining PSA values regardless of their 
group was the controlled intake of 500 ml of fluids 
(either pomegranate juice or placebo) in addition to 
other daily fluids. In the absence of a 
non-interventional control this influence cannot be 
ruled out. Regarding the value of pomegranate in the 
setting of advanced prostate cancer this variable plays 
no role as it appeared in both groups.  
Due to the design of a verum-containing treat-
ment period for all patients (second part of the trial) 
we were able to analyze PSA levels of all men who 
started with placebo in comparison to the PSA levels 
after a subsequent four-week consumption phase of 
250 ml of PJ, equivalent to 573 mg/ml phenol gallic 
acids (Table 2A placebo day 1-28 versus placebo day 
28-56 panel). Here, no difference between the placebo 
and the verum period in group A was detected (41% 
vs. 24% progress, 57% vs. 74% stabilization, 2% vs. 2% 
response; p=0.08) indicating that the pomegranate 
ingredients of the drink were not responsible for any 
change.  
The absolute PSA level declines observed in this 
study did not reach clinical significance in either co-
hort when a PSA level decrease of ≥ 50% is defined as 
objective response. Overall, 5 responses of PSA level 
decline ≥ 30%, with a non-significant difference be-
tween the groups, were recorded at the end of the 
randomized part of the trial. 
With respect to the impact of pomegranate juice 
in early prostate cancer patients there have been two 
reports [11] and a phase III study is currently under-
way with reports expected in 2012 (NCT00413530). 
Table 3 illustrates the differences between the clinical 
data available to date. The major difference of the 
studies is that the two previously reported studies in 
early prostate cancer patients focussed on PSADT and 
had longer observational periods. Within the context 
of low PSA values (<5 ng/ml, median 2.2) and mini-
mal active disease this is an adequate approach. Our 
study included patients with more advanced disease 
and higher PSA values (median 19.7 ng/ml). These 
patients are often to start their next therapy within a 
short period of time. Thus, these patients cannot be 
observed for an extended time period. Hence, PSADT 
would not have been a good end point. However, 
with a half-life of PSA of 2.2 days ([18]) we calculated 
that any meaningful changes in the PSA course of 
these patients should be readily detectable by 4 inde-
pendent measurements at least 14 days apart and 
within a follow-up of two months.  
An unexpected limitation of our study is a cer-
tain heterogeneity of the included patient cohort. For 
example the recorded number of metastases in our 
study seems to indicate an imbalance in favor of the 
placebo arm. In this regard it has to be considered that 
no imaging diagnostics were performed at study en-
try. Baseline diagnostics included clinical examination 
and PSA level determination. Metastatic status was 
derived from previous clinical reports. Data concern-
ing initial metastases (M1 at operation) was available 
in 58% (A) and 69% (B) of patients. The apparent im-
balance could be due to under-diagnosing or un-
der-reporting in the placebo group. Further support-
ing this notion is the fact that the average entry PSA 
level showed no difference with a median of 19 ng/ml 
(mean 90) in the placebo group and a median of 21 
ng/ml (mean 60) in the interventional arm. When we 
examined responses of those men with castration re-
sistant prostate cancer only (68% of all study partici-
pants), no difference between the groups was noted 
(Table 2B). Taken together, this imbalance, if present, 
should have had no impact on the results. 
Table 3: Comparison of this study with previously reported clinical studies. 
Criteria Pantuck et al. Paller et al. Stenner et al. 
Study design Single arm Phase II 2 intervention Arms Placebo controlled 
Observation period 18months/progression 18months/progression 2months 
PSA (ng/ml) 0.5-5 0.5-5 >5  
[Median; Mean,SD] [1.05; 2.23±2.58] [NR] [19.7; 74.5±166] 
Metastatic disease allowed No No Yes[23%] 
Grading Gleason ≤7 Gleason any no restriction 
[% Gleason ≥8] [0%] [10%] [49%] 
Pretreatment allowed S, RT S, RT, B, C S, RT, B, C 
PJ, Gallic Acid equivalent 570mg/ml (8 oz.) 1 and 3 Caps* 1146mg/ml (phase1) 
Daily intake  (1 caps= 8 oz.) 573mg/ml (phase2) 
Duration of treatment 12 months 18months+ 2months 
Abbreviations: S, surgery; RT, radiotherapy; B, brachytherapy; C, cryotherapy 
square brackets [] indicate data collected within respective study. NR data not reported 
*One POMx capsule is equivalent to an 8 oz. glass of juice 
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 The molecular pathway of pivotal importance in 
prostate cancer is the IGF-1/AKT/mTOR pathway. 
Bi-allelic loss of PTEN in about 50% of metastatic 
prostate cancers [19] results in over activation of this 
pathway, rendering targeted therapy an attractive 
concept. Everolimus like pomegranate is an inhibitor 
of the IGF-1/AKT/mTOR pathway (9). Single agent 
everolimus in a patient collective comparable to the 
one in this study has yielded PSA response rates in 
the range of 3% (PSA decrease ≥50%) and 11% (≥30%) 
[20]. This result indicates some activity but also the 
need of refining the therapeutic approaches directed 
against this pathway. In a preclinical model 
IGF-1/AKT/mTOR stimulation drives cancer cells 
into hormone insensitivity and leads to neuroendo-
crine differentiation [21]. This could explain why 
everolimus and pomegranate as inhibitors of this 
pathway may not be very effective in patients that 
have failed anti-hormonal therapy and should rather 
be considered earlier in a treatment algorithm. 
The analysis of our prospective study shows that 
pomegranate in the form of a daily beverage does not 
alter the course of PSA in patients with advanced 
prostate cancer regardless of the dosage. The maxi-
mum dose used here was twice as high as in the pre-
viously published study [10]. However, the dosage of 
pomegranate does not seem to be of utmost im-
portance. Two studies [10, 11] have shown no differ-
ences in the increase of PSADT when comparing 8 oz 
to a higher dose of 24 oz (6.9 months versus 5.3 
months, p=0.92). 
In conclusion, pomegranate beverage had no 
significant impact on PSA progression in patients 
with recurrent and advanced prostate cancer when 
compared to placebo. The hitherto published benefit 
of pomegranate juice seems to be restricted to early 
and well differentiated prostate cancer. Our results 
provide important information for the design and 
patient selection within further trials with pomegran-
ate. 
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